Actively Recruiting
Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg)
Led by Medialis Ltd. · Updated on 2023-10-23
100
Participants Needed
1
Research Sites
416 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Coronavirus Disease 2019 (COVID-19) is a newly emerged disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic is having a large impact on the mental and physical health of patients, yet data on the quality of life of post-COVID-19 patients is lacking. There are currently no post-COVID-19 specific measures for quality of life, particularly none which include the views of post-COVID-19 patients themselves. This observational study will recruit participants to contribute their preferences to the creation of a post-COVID-19 specific patient-reported measure on post-COVID-19 quality of life. Participants will be split into three groups: those who were not hospitalised; those who were hospitalised but not in intensive care units; and those who were hospitalised and in intensive care units. The creation of this measure will form phase 1 of the study, with 30-60 participants (10-20 in each group above) recruited to complete online surveys to find out their preferences of areas of life to include in such a measure. This will involve 3 online surveys, 1) to ask which areas of life they feel are impacted and how; 2) to find consensus about the areas to be included; 3) to weight the relevance of these areas in relation to each other. In phase 2 recruitment will open to additional participants and all participants will be asked to complete the finalised post-COVID-19 quality of life measure once a month for 12 months, aiming for a minimum of 100 participants at this stage. All participants will also be asked to complete a demographic questionnaire to inform the analysis of the data.
CONDITIONS
Official Title
Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The participant has had either a confirmed COVID-19 test while infected or a confirmed COVID-19 antibody test post-infection (Phase One) or a confirmed COVID-19 test, antibody test, or clinical diagnosis of COVID-19 (Phase Two)
- The participant is aged 18 years or older
- The participant is capable of providing informed consent
- The participant can read, write and converse in English
- The participant can comply with the study schedule
You will not qualify if you...
- The participant does not have a confirmed COVID-19 test, antibody test, or clinical diagnosis of COVID-19
- The participant is aged under 18 years
- The participant is not capable of giving informed consent
- The participant is unable to read, write and converse in English
- The participant is unable to comply with study schedule data collection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medialis
Oxford, United Kingdom, OX16 0AH
Actively Recruiting
Research Team
O
Omolade Femi-Ajao, PhD
CONTACT
R
Ravi Jandhyala
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here